

FORM 7

MONTHLY PROGRESS REPORT

Name of Listed Issuer: CB2 Insights Inc. (the "Issuer").

Trading Symbol: CBII

Number of Outstanding Listed Securities: 93,575,268

Date: March 31, 2020

Report on Business

1. Provide a general overview and discussion of the development of the Issuer's business and operations over the previous month. Where the Issuer was inactive disclose this fact.

On March 30, 2020 the Issuer launched the medical cannabis industry's first interactive dashboard which gives any industry stakeholders access to key patient insights derived from the Company's clinical operations. The tool (link: <https://cb2insights.ca/data>) is free to use and was created in order to answer hundreds of inbound questions from global industry stakeholders including government agencies and major research groups. The dashboard also allows users to submit additional data requests directly to the Company's research and data team.

"Over the last several months, we have seen hundreds of requests for data and insights from stakeholders such as government bodies, researchers, pharma companies, physicians, hospital networks, cultivators, and the list goes on," said Prad Sekar, CEO of CB2 Insights. "This new interactive tool will allow these groups to access the primary insights that they are requesting quickly and gain real-time results. But with the millions of data points that we monitor, they also have the opportunity to discuss with us how they can receive more tailored results that match their needs. And more importantly, solidify CB2 Insights as one of the sole providers of these types of insights in this industry."

The tool provides users with the ability to filter results of over hundreds of thousands of anonymized de-identified clinical interactions in categories such as primary medical condition, age grouping, previous cannabis experience, other medication being used, cannabinoid profile usage and the patient's positive and negative effects of their cannabis treatment. With millions of datapoints, the Company has the ability to provide an unparalleled amount of customized insights to stakeholders.

“Accurate, structured data is at the center of everything healthcare companies do in this day and age,” said Tom Brogan, Director, CB2 Insights and former IQVIA Executive. “Access to the type of medical cannabis data that CB2 holds is not only rare, it is essential to truly transition these alternative treatments into mainstream healthcare. This new tool is certainly a powerful bridge to expedite that process across a wide range of industry stakeholders.”

CB2 Insights owns one of the largest group of multi-state medical cannabis evaluation and education centres with multiple clinic brands operating in states such as Colorado, Massachusetts, Maryland, New Jersey, Pennsylvania, Connecticut, Maine and others. Within these operations, physicians, nurse practitioners and cannabis educators treat and support more than 100,000 patients each year across 60 different primary conditions. With high patient diversity seeking treatment for everything from chronic pain to sleep disorders to anxiety and depression, CB2 Insights has access to anonymized and de-identified insights into one of the world’s largest and richest data sets derived from the point-of-care. In turn, the Company’s goal is to make these insights available to key industry stakeholders and shifting many of their reliance solely on anecdotal data only so they may advance the application, acceptance and regulation of medical cannabis and cannabis derived treatments to improve patient outcomes globally.

The new dashboard is being made free to all stakeholders to use directly through CB2 Insights’ website. Users can submit requests for additional insights and data categories below the dashboard. CB2 Insights’ research and data teams have been receiving hundreds of requests and will continue to work directly with stakeholders to advance the understanding of how medical cannabis can play a role in traditional healthcare models.

All interested parties can access CB2 Insights’ interactive dashboard here: <https://cb2insights.ca/data>.

2. Provide a general overview and discussion of the activities of management.
None other than as described above.
3. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.
n/a
4. Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.
n/a

5. Describe any new business relationships entered into between the Issuer, the Issuer's affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.
n/a
6. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer's affiliates or third parties or cancellation of any financing arrangements that have been previously announced.
n/a
7. Describe any acquisitions by the Issuer or dispositions of the Issuer's assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer and provide details of the relationship.
n/a
8. Describe the acquisition of new customers or loss of customers.
n/a
9. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trade-marks.
n/a
10. Report on any employee hirings, terminations or lay-offs with details of anticipated length of lay-offs.
n/a
11. Report on any labour disputes and resolutions of those disputes if applicable.
n/a
12. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.
n/a
13. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.
n/a
14. Provide details of any securities issued and options or warrants granted.

15. Provide details of any loans to or by Related Persons.
n/a
16. Provide details of any changes in directors, officers or committee members.
n/a
17. Discuss any trends which are likely to impact the Issuer including trends in the Issuer's market(s) or political/regulatory trends.

We are adapting our business given current market and regulatory conditions throughout the US and beyond. It is true that COVID-19 is affecting each and every State that we operate in within the US.

Our clinical services remain open to servicing patients in each of our States – whether currently in mandatory closure or not. As a medical service, our business is permitted to continue to operate through this crisis, to support patients in need. However, we have had to make changes to our operating model to manage the safety of our clinicians, staff and patients. We have been approved by all States to provide telemedicine and telehealth services to all existing patients. This change has been quite seamless. We are limited in our ability to service net new patients in certain States due to telemedicine regulations, but we are hopeful those will be amended, and we will be able to serve all patients in the near-term.

Additionally, while we have had to make temporary layoffs for some clinical staff due to the shut down of physical locations, we have maintained most employees to continue to support the increase in patient volumes.

We also see this as an opportunity to expand our services in markets we are not currently serving. With new telemedicine regulations in place for non-CB2 operating States, we expect to mobilize services to these States in short order.

Certificate of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. As of the date hereof there is no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CNSX Policy 1).
4. All of the information in this Form 7 Monthly Progress Report is true.

Dated April 7, 2020.

Kash Qureshi
Name of Director or Senior
Officer

"signed"
Signature
COO
Official Capacity

Issuer Details Name of Issuer CB2 Insights Inc.	For Month End March, 2020	Date of Report YY/MM/DD 20/04/07
Issuer Address 5045 Orbitor Drive, Building 11, Unit 300		
City/Province/Postal Code Mississauga, ON L4W 4Y4	Issuer Fax No. ()	Issuer Telephone No. (855) 874-4999
Contact Name Catherine Beckett	Contact Position Manager Corporate Affairs	Contact Telephone No. 416-642-1807